Alternatives to amyloid for Alzheimer's disease therapies—a symposium report

Jennifer Cable, David M. Holtzman, Bradley T. Hyman, Malú Gámez Tansey, Marco Colonna, Manolis Kellis, Roberta D. Brinton, Marilyn Albert, Cheryl L. Wellington, Sangram S. Sisodia, Rudolph E. Tanzi

Research output: Contribution to journalArticlepeer-review

1 Scopus citations

Abstract

For decades, Alzheimer's disease research has focused on amyloid as the primary pathogenic agent. This focus has driven the development of numerous amyloid-targeting therapies; however, with one possible exception, none of these therapies have been effective in preventing or delaying cognitive decline in patients, and there are no approved disease-modifying agents. It is becoming more apparent that alternative drug targets are needed to address this complex disease. An increased understanding of Alzheimer's disease pathology has highlighted the need to target the appropriate disease pathology at the appropriate time in the disease course. Preclinical and early clinical studies have focused on targets, including inflammation, tau, vascular health, and the microbiome. This report summarizes the presentations from a New York Academy of Sciences' one-day symposium entitled “Alzheimer's Disease Therapeutics: Alternatives to Amyloid,” held on November 20, 2019.

Original languageEnglish
Pages (from-to)3-14
Number of pages12
JournalAnnals of the New York Academy of Sciences
Volume1475
Issue number1
DOIs
StatePublished - Jul 3 2020

Keywords

  • allopregnanolone
  • Alzheimer's disease
  • amyloid
  • APOE
  • cognitive impairment
  • dementia
  • HDL
  • microbiome
  • microglia
  • neuroinflammation
  • tau
  • TREM2

Fingerprint Dive into the research topics of 'Alternatives to amyloid for Alzheimer's disease therapies—a symposium report'. Together they form a unique fingerprint.

Cite this